I am pleased to announce that Dr. Julia D. Visgauss, MD, has been appointed Division Chief of Orthopaedic Oncology, effective April 1, 2025.
Dr. Visgauss brings extensive experience in both academic medicine and clinical practice. She currently serves as an Assistant Professor in the Department of Orthopaedic Surgery at Duke University and is a member of the Duke Cancer Institute. She earned her M.D. from Johns Hopkins University School of Medicine, completed her Orthopaedic Surgery Residency at Duke University, and pursued a Musculoskeletal Oncology Fellowship at Mount Sinai Hospital in Toronto, Canada. In 2018, she returned to Duke to continue her impactful work.
Her research has significantly advanced patient care, particularly in sarcoma treatment, with a focus on chondrosarcoma, a bone cancer with limited treatment options beyond surgery. Dr. Visgauss’s translational research examines cellular disruptions and immune interactions contributing to cancer metastasis, intending to develop targeted therapies to improve patient outcomes.
In addition to her clinical and academic achievements, Dr. Visgauss has demonstrated strong leadership within the department by serving as the Associate Chief of our Oncology Division. Her excellence has been recognized with numerous accolades, including induction into the prestigious Alpha Omega Alpha (AOA) honor society and participation in the AOA Emerging Leaders program.
I also want to thank Dr. Will Eward, MD, DVM, for his outstanding leadership as Division Chief of Orthopaedic Oncology since 2022. With this transition, Dr. Eward will focus on his important role as Director of our Residency Program.
Please join me in congratulating Dr. Visgauss on this well-deserved appointment and thanking Dr. Eward for his service. We look forward to the continued advancements and leadership she will bring to Duke Orthopaedic Oncology and the broader medical community.
All the best,
Ben